Look back at pharma news in week to July 27

By Barbara Obstoj-Cardwell. Editor

Last week saw the surprise announcement from Gilead Sciences that both its chief executive and chairman are to leave the company. On the M&A front last week, Sangamo Therapeutics decision to acquire the small French biotech TxCell featured. Regulatory news included a US Food and Drug Administration approval for Agios rare cancer treatment Tibsovo, while an FDA advisory panel voted against approval of GlaxoSmithKline’s Nucala for COPD. Also disappointing, was the latest data on Biogen and Eisai’s Alzheimer’s candidate BAN2401.

Gilead: Full circle back to dominant HIV business as founders exit left